Shares of Veracyte Inc. (NASDAQ:VCYT) have been assigned a consensus recommendation of “Buy” from the six ratings firms that are currently covering the stock. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $10.55.

VCYT has been the subject of a number of recent analyst reports. Zacks Investment Research upgraded shares of Veracyte from a “sell” rating to a “hold” rating in a report on Thursday, October 27th. Cantor Fitzgerald set a $13.00 price target on shares of Veracyte and gave the stock a “buy” rating in a report on Thursday, September 8th. Piper Jaffray Cos. restated an “overweight” rating and set a $10.00 price target (down previously from $12.00) on shares of Veracyte in a report on Thursday, August 4th. Leerink Swann restated an “outperform” rating and set a $12.00 price target on shares of Veracyte in a report on Monday, November 14th. Finally, William Blair reaffirmed an “outperform” rating on shares of Veracyte in a research report on Tuesday, October 18th.

Several institutional investors have recently bought and sold shares of VCYT. Rhumbline Advisers boosted its position in Veracyte by 1.1% in the third quarter. Rhumbline Advisers now owns 13,143 shares of the company’s stock worth $100,000 after buying an additional 140 shares during the last quarter. Strs Ohio boosted its position in shares of Veracyte by 638.5% in the third quarter. Strs Ohio now owns 14,031 shares of the company’s stock valued at $106,000 after buying an additional 12,131 shares in the last quarter. Kopp Investment Advisors LLC boosted its position in shares of Veracyte by 55.7% in the second quarter. Kopp Investment Advisors LLC now owns 21,975 shares of the company’s stock valued at $111,000 after buying an additional 7,860 shares in the last quarter. Royce & Associates LP acquired a new position in shares of Veracyte during the second quarter valued at approximately $136,000. Finally, California State Teachers Retirement System boosted its position in shares of Veracyte by 2.1% in the second quarter. California State Teachers Retirement System now owns 29,387 shares of the company’s stock valued at $148,000 after buying an additional 600 shares in the last quarter. 47.49% of the stock is owned by hedge funds and other institutional investors.

Veracyte (NASDAQ:VCYT) opened at 7.73 on Tuesday. The firm’s market capitalization is $216.05 million. Veracyte has a 12 month low of $4.21 and a 12 month high of $8.45. The stock’s 50 day moving average price is $7.44 and its 200-day moving average price is $6.04.

Veracyte (NASDAQ:VCYT) last announced its quarterly earnings results on Thursday, November 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.36) by $0.16. The business earned $18.60 million during the quarter, compared to the consensus estimate of $15.76 million. Veracyte had a negative net margin of 57.45% and a negative return on equity of 88.36%. The business’s revenue was up 50.7% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.32) EPS. Equities analysts forecast that Veracyte will post ($1.26) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Veracyte Inc. (VCYT) Receives $10.55 Average PT from Brokerages” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2016/11/25/veracyte-inc-vcyt-receives-10-55-average-pt-from-brokerages.html.

About Veracyte

Veracyte, Inc is a molecular diagnostics company. The Company is engaged in developing and delivering genomic solutions that resolve diagnostic ambiguity and enable physicians to make informed treatment decisions at an early-stage in patient care. The Company targets diseases in which various patients undergo diagnostic procedures that could be avoided with diagnosis from a cytology sample taken preoperatively.

5 Day Chart for NASDAQ:VCYT

Receive News & Stock Ratings for Veracyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte Inc. and related stocks with our FREE daily email newsletter.